A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: HER2-positive Breast Cancer|Invasive Carcinoma of the Breast|Breast Cancer|Node Negative Breast Cancer|Micrometastasis Breast Cancer|Hormone Receptor Positive Breast Cancer
Interventions: COMBINATION_PRODUCT: Pertuzumab+TRASTUZUMAB|DRUG: ADJUVANT ENDOCRINE THERAPY
Sponsor: Dana-Farber Cancer Institute
Collaborators: Genentech, Inc.